Stock and sector set for re rating, no longer seen as defencive. Heading for skid row, high PE ratios no longer justified. The go go days for this sector are confined to history. Drug pipelines are running dry; absence of blockbusters on the horizon; patents under pressure from the generics. The days of price fixing are a distant memory.
No chart(s) can change the outlook for the sector or AstraZeneca, no doubt, traders will make money regardless of where the stock(s) goes but long term investors are set to see a steady erosion of capital. Better value elsewhere.
No chart(s) can change the outlook for the sector or AstraZeneca, no doubt, traders will make money regardless of where the stock(s) goes but long term investors are set to see a steady erosion of capital. Better value elsewhere.